Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Annie C. Lajoie, Sébastien Bonnet, Yves Lacasse, Jean-Christophe Lega, Steeve Provencher. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018

Member's Comments

No comment yet.

Related content which might interest you: Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001 New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Pulmonary pressure at rest and during slight exercise might have prognostic relevance in patients at risk for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Early improvements predict outcomes in pulmonary arterial hypertension Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Source: Eur Respir J 2007; 29: 432-434 Year: 2007 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Clinical trials in pulmonary arterial hypertension: what they tell us Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019